Affinity and selectivity of [ 11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo

Synapse

Volumn 66, Issue 6, 2012, Pages 489-500

  Gallezot, Jean Dominique ^a   Beaver, John D ^b   Gunn, Roger N ^b   Nabulsi, Nabeel ^a   Weinzimmer, David ^a   Singhal, Tarun ^a   Slifstein, Mark ^c   Fowles, Krista ^a   Ding, Yu Shin ^a   Huang, Yiyun ^a   Laruelle, Marc ^b   Carson, Richard E ^a   Rabiner, Eugenii A ^b  

^a YALE UNIVERSITY   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Brain; D2 receptor; D3 receptor; In vivo; PET; Primate

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NAXAGOLIDE; NAXAGOLIDEB C 11; UNCLASSIFIED DRUG; 4 PROPYL 3,4,4A,5,6,10B HEXAHYDRO 2H NAPHTHO(1,2 B)(1,4)OXAZIN 9 OL; 4-PROPYL-3,4,4A,5,6,10B-HEXAHYDRO-2H-NAPHTHO(1,2-B)(1,4)OXAZIN-9-OL; BENZOXAZINE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NAPHTHOL DERIVATIVE; OXAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; IN VIVO STUDY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; RHESUS MONKEY; ANIMAL; BINDING COMPETITION; BRAIN; CHEMISTRY; ENZYME SPECIFICITY; MACACA MULATTA; METABOLISM; SCINTISCANNING;

ANIMALS; BENZOXAZINES; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; DOPAMINE AGONISTS; FEMALE; MACACA MULATTA; NAPHTHOLS; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SUBSTRATE SPECIFICITY;

EID: 84862802562     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21535     Document Type: Article

References (26)

1. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104-8109.
2. Beck J, Arnold K. 1977. Parameter estimation in engineering and science. Chapter 7.7.1. Wiley, New York, NY.
3. Bevington P, Robinson D. 2003. Data reduction and error analysis for the physical sciences. Chapter 3. McGraw-Hill, New York, NY.
4. 11C]-propionyl chloride. Proceedings of the XIIth International Symposium on Radiopharmaceutical Chemistry, Uppsala, Sweden. p 565-566.
5. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13: 24-42.
6. 3 dopamine receptor. J Pharmacol Exp Ther 268: 417-426.
7. 2-dopamine receptors in the monkey brain. Synapse 25: 321-325.
8. 11C]-(+)-PHNO PET study. Neuropsychopharmacology 34: 1078-1086.
9. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
10. Lammertsma AA, Hume SP. 1996. Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
11. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW. 1997. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1-14.
12. Levant B. 1997. The D3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 49: 231-252.
13. 3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89: 8155-8159.
14. Marquardt D. 1963. An algorithm for least square estimation of nonlinear parameters. SIAM J Appl Math 11: 431-441.
15. Mizrahi R, Houle S, Vitcu I, Ng A, Wilson AA. 2010. Side effects profile in humans of (11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET. J Nucl Med 51: 496-497.
16. Nai YH, Cunneen ML, Dimber RS, Hallett WA, Searle GE. 2011. The relationship between radioactive dose and precision of outcome parameters in quantitative PET imaging of the human brain. Presented at BrainPET 2011 meeting, Barcelona. Available at
17. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M. 2006. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60:485-495.
18. 11C]PHNO in the primate brain. Neuroimage 41 ( Suppl. 2): T39-T39.
19. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, Gunn RN, Laruelle MA. 2009. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 63: 782-793.
20. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ. 2000. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294: 1154-1165.
21. 3 receptor antagonist. Biol Psychiatry 68: 392-399.
22. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
23. 11C]-(+)-PHNO: Dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
24. van Vliet L, Rodenhuis N, Dijkstra D, Wikstrom H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Lundmark M. 2000. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR, 10bR)-(+)-trans-3, 4, 4a, 10b-tetrahydro-4-n-propyl-2H, 5H-[1]benzopropyno[4, 3-b]-1, 4-oxazin-9-ol (PD128907). J Med Chem 43: 2871-2882.
25. Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S. 2002. Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry 7: 233.
26. 11C]-(+)-4-propyl-3, 4, 4a, 5, 6, 10b-hexahydro-2h-naphtho[1, 2-B][1, 4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160.